Kura Oncology, Inc. (KURA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$11.66

From 52W high−13.69%

Volume2.56M

Market cap$1.04B

P/E (TTM)—

P/S (TTM)13.5x

Div yield—

Key dataSep 18, 2026

Open

$11.66

From 52W high

−13.69%

Volume

2.56M

Market cap

$1.04B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.9x

P/E (TTM)

—

RSI (14)

49.5

MomentumView details →

1D Return

+0.09%

YTD Return

+12.80%

SummaryUpdated Jun 1, 2026

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. The company went public in September 2015 and focuses on developing precision medicines for cancer treatment. Kura has built a pipeline of small molecule drug candidates designed to target specific genetic mutations and pathways involved in various cancers, with its lead programs showing particular promise in blood cancers like acute myeloid leukemia (AML) and solid tumors including gastrointestinal stromal tumors (GIST).

Ask drillr about Kura Oncology, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.9x

EV/Sales

7.1x

P/S (TTM)

13.5x

P/B (TTM)

21.5x

ProfitabilityView details →

Gross Margin

94.73%

Net Margin

−384.30%

EBITDA Margin

−378.60%

ROE (TTM)

−612.78%

ROA (TTM)

−50.49%

Asset Turnover

0.12x

GrowthView details →

Revenue YoY

−7.27%

EPS YoY

−49.12%

FCF YoY

—

Revenue CAGR 3Y

+25.24%

EPS CAGR 3Y

−57.43%

EBITDA YoY

−51.31%

MomentumView details →

1D Return

+0.09%

YTD Return

+12.80%

1Y Return

+42.06%

RSI (14)

49.5

vs 50D SMA

+4.93%

vs 200D SMA

+19.40%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

4.73x

Quick Ratio

4.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.77

EPS Surprise

12.23%

Beats (12Q)

8/12

Next Q EPS Est

−$0.82

Avg Surprise (4Q)

−156.52%

Rev Surprise

3.53%

Financials snapshotView financials →

Revenue (TTM)

77.22M

Net Income (TTM)

−296.77M

Op. CF (TTM)

−111.76M

Next earningsNov 3, 2026 →

Latest newsMore news →

Kura Oncology launched Caspian Therapeutics, a separately financed company to advance menin inhibitors for diabetes, with $50 million financing led by BVF Partners.10d ago

Kura Oncology, Inc. appointed Jennifer Fulk as Chief Financial Officer, effective September 8, 2026.11d ago

Similar companies

Maravai LifeSciences Holdings, Inc.MRVI Cloudbreak Pharma Inc.02592.HK Monte Rosa Therapeutics, Inc.GLUE MoonLake ImmunotherapeuticsMLTX Corvus Pharmaceuticals, Inc.CRVS Janux Therapeutics, Inc.JANX Find similar companies →

Latest newsMore news →

Kura Oncology launched Caspian Therapeutics, a separately financed company to advance menin inhibitors for diabetes, with $50 million financing led by BVF Partners.10d ago Kura Oncology, Inc. appointed Jennifer Fulk as Chief Financial Officer, effective September 8, 2026.11d ago